C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Oct 31, 2024
Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA
Read more at globenewswire.comNASDAQ:CCCC (4/21/2025, 3:55:05 PM)
1.375
+0.13 (+10%)
Find more stocks in the Stock Screener
CCCC Latest News and Analysis
11 days ago - ChartmillWhich stocks are moving before the opening bell on Thursday?As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
